PLAT and Stroke: Since the Food and Drug Administration (FDA) approval of tissue plasminogen activator (tPA) for treatment of acute ischemic stroke in 1996, intravenous tPA (ivtPA) administration within a 3–4.5 hours window postsroke has been the mainstream of stroke intervention [1].